Can positron emission tomography with 18F fluorodeoxyglucose after first line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity? - Spaepen,K.; Stoobants,S.; Dupont,P.; Thomas,J.; Vandenberghe,P.; Blazarini,J.; de Wolf-Peeters,C.; Mortelmans,L.; Verhoef,G. (Brit J Hematol, 2001)